dexamethasone implant
Sponsors
Northern California Retina Vitreous Associates, Novartis Pharmaceuticals, Ludwig-Maximilians - University of Munich, Johns Hopkins University, Allergan
Conditions
Branch Retinal Vein OcclusionDiabetes MellitusDiabetic Macular EdemaDiabetic RetinopathyHyperglycaemia (Diabetic)Macular EdemaMacular Edema Caused by Retinal Vein OcclusionMacular Edema Due to Diabetes Mellitus
Phase 2
Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery
CompletedNCT01284478
Start: 2011-01-31End: 2012-10-31Updated: 2012-10-04
Ozurdex for Retinal Vein Occlusion Study (ORVO Study)
CompletedNCT01790685
Start: 2013-02-28End: 2014-12-31Updated: 2015-04-22
Diabetic Macular Edema Treated With Ozurdex (DMEO)
CompletedNCT01951066
Start: 2013-10-31End: 2015-12-31Updated: 2016-09-29
Phase 3
Phase 4
Dexamethasone-implant for the Treatment of RVO
CompletedNCT01767545
Start: 2010-09-30End: 2012-02-29Updated: 2013-01-14
A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion
CompletedNCT01903720
Start: 2013-07-16End: 2015-03-30Updated: 2019-04-17
Ranibizumab vs Dexamethasone Implant in Vitrectomized Eyes With Diabetic Macular Edema
CompletedNCT04089605
Start: 2017-06-01End: 2019-04-30Updated: 2019-09-13
Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subjects With Diabetic Macular Edema
CompletedNCT04411693
Start: 2020-04-10End: 2025-05-14Updated: 2026-07-29
Prospective Trial of Dexamethasone implAnt for Treatment Naïve diabeTic Macular Edema
NCT04448496
Start: 2020-06-22End: 2021-12-31Target: 49Updated: 2020-06-26
Unknown Phase
OCT and OCT-Angiography Biomarkers of Treatment Response to Dexamethasone Implant in Macular Edema Due to Retinal Vascular Diseases - DME and RVO
RecruitingNCT06332690
Start: 2023-10-17End: 2025-12-31Target: 50Updated: 2024-03-27
Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant
RecruitingNCT06984822
Start: 2025-08-01End: 2028-12-31Target: 150Updated: 2025-11-21